Perrigo Company plc Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent of $1.00 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent · last filed 2026-08-05
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2026-06-27 was $1.00M.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2026-03-28 was $0.00.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-12-31 was $52.90M, a 37.05% increase year-over-year.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-09-27 was $500.00K.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2025 was -$18.90M, a 164.51% decline from fiscal 2024.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2024 was $29.30M.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2023 was -$17.70M, a 1280.00% decline from fiscal 2022.
- Perrigo Company plc other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2022 was $1.50M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-27 | $1.00M 10-Q · filed 2026-08-05 | $1.00M 10-Q · filed 2026-08-05 | $53.90M derived: sum of 3 quarters · filed 2026-08-05 | $54.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $0.00 10-Q · filed 2026-05-06 | $52.90M derived: sum of 2 quarters · filed 2026-05-06 | $53.40M derived: sum of 3 quarters · filed 2026-05-06 | -$100.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $52.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $53.40M derived: sum of 2 quarters · filed 2026-02-26 | -$100.00K derived: sum of 3 quarters · filed 2026-08-05 | -$18.90M 10-K · filed 2026-02-26 |
| 2025-09-27 | $500.00K 10-Q · filed 2025-11-05 | -$53.00M derived: sum of 2 quarters · filed 2026-08-05 | -$71.80M 10-Q · filed 2025-11-05 | -$33.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$53.50M 10-Q · filed 2026-08-05 | -$72.30M 10-Q · filed 2026-08-05 | -$33.60M derived: sum of 3 quarters · filed 2026-08-05 | -$52.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$18.70M 10-Q · filed 2026-05-06 | $19.90M derived: sum of 2 quarters · filed 2026-05-06 | $900.00K derived: sum of 3 quarters · filed 2026-05-06 | $900.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $38.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.60M derived: sum of 2 quarters · filed 2026-02-26 | $19.60M derived: sum of 3 quarters · filed 2026-02-26 | $29.30M 10-K · filed 2026-02-26 |
| 2024-09-28 | -$19.00M 10-Q · filed 2025-11-05 | -$19.00M derived: sum of 2 quarters · filed 2025-11-05 | -$9.30M 10-Q · filed 2025-11-05 | |
| 2024-06-29 | $0.00 10-Q · filed 2025-08-06 | $9.70M 10-Q · filed 2025-08-06 | ||
| 2024-03-30 | $9.70M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$17.70M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $1.50M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |